| | | | |
| | | | Exhibit 5.1 |
| | ![LOGO](https://capedge.com/proxy/S-4/0001193125-20-234854/g946576g0826030324013.jpg) | | One Financial Center Boston, MA 02111 617 542 6000 mintz.com |
August 28, 2020
Spring Bank Pharmaceuticals, Inc.
35 Parkwood Drive, Suite 210
Hopkinton, MA 01748
Ladies and Gentlemen:
We have acted as counsel to Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of a registration statement on Form S-4 (including all exhibits thereto, the “Registration Statement”), for the registration under the Securities Act of 1933, as amended (the “Securities Act”), of 35,256,571 shares (as such number may be adjusted after giving effect to the reverse stock split referred to in the Registration Statement, the “Shares”) of the Company’s common stock, par value $0.0001 per share, expected to be issued pursuant to that certain Share Exchange Agreement, dated as of July 29, 2020, by and among the Company, F-star Therapeutics Limited, a private company registered in England and Wales (“F-star”) and the holders of issued and outstanding capital shares and convertible loan notes of F-star party thereto (the “Exchange Agreement”).
In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of: (i) the Amended and Restated Certificate of Incorporation of the Company; (ii) the Amended and Restated Bylaws of the Company; (iii) certain resolutions of the Board of Directors of the Company (the “Board”) relating to the Exchange Agreement; and (iv) the Registration Statement. In addition, we have examined originals or copies, certified or otherwise identified to our satisfaction, of certain other corporate records, documents, instruments and certificates of public officials and of the Company, and we have made such inquiries of officers of the Company and public officials and considered such questions of law as we have deemed necessary for purposes of rendering the opinions set forth herein. Our opinions are limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought to independently verify such matters. In addition, in rendering this opinion, we have assumed that prior to the issuance of any of the Shares, the Company’s Amended and Restated Certificate of Incorporation of the Company, as amended, will be further amended to effect a reverse stock split as provided in the Registration Statement, and that all other approvals referred to in the Registration Statement relating to the issuance of the Shares have become effective.